Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credit: iStock
A key chemical used in many gel nail polish products has been banned in England, Wales and Scotland.
The “gel nail ban” applies to one ingredient — Trimethylbenzoyl Diphenylphosphine Oxide, commonly known as TPO. It is used in some gel manicures to help the polish achieve a glossy finish and cure properly.
TPO (Trimethylbenzoyl Diphenylphosphine Oxide) is a photoinitiator commonly used in UV- and LED-cured nail products. It makes the varnish more durable and helps it hold its color for longer.
The European Union banned TPO in cosmetic products from September 1, 2025. In the UK, the ban came into effect on August 15.
The ban means manufacturers can no longer sell new products containing TPO. However, salons can continue to offer gel manicures using existing TPO-containing products until February 14, 2027, or until their stocks run out.
Nail technicians will not be able to purchase new stock containing TPO. TPO-containing products continue to be used in the US, Australia and Asia.
The ban follows several animal studies that linked TPO to long-term fertility damage and reproductive issues.
Caroline Rainsford, Director of Science at The Cosmetic, Toiletry and Perfumery Association (CTPA), said the EU ban was based on the chemical's hazardous properties and how a substance might behave in a “worst-case” situation when the body is exposed to a very large amount.
“This is not how TPO is used in cosmetics. The amount of this ingredient used in nail products is over a thousand times less than the amount which could have any negative effect on fertility, and these products are applied to the nail, so the potential for the ingredient to be absorbed into our bodies is even smaller,” Rainsford was quoted as saying in media reports.
TPO is used only in some gel polishes and is not found in traditional air-dried nail polishes. There are already TPO-free gels on the market, and many salons use these products. While some alternatives may belong to the same chemical family, different compounds have different safety ratings.
TPO-free gel systems now use alternative photoinitiators that meet regulatory standards while still delivering similar results.
TPO-free options are available across:
Credit: iStock
The UK Health Security Agency (UKHSA) has declared a national outbreak of Salmonella in the UK, with health officials suspecting a possible link to imported eggs.
According to the UKHSA, 207 confirmed cases were detected between August 11, 2025, and August 1, 2026, with the majority reported in 2026. Of those affected, 38% were admitted to hospital, and one person has died.
Cases have been reported across the UK:
Among cases in England, London reported 47 cases, the highest number, followed by Yorkshire and the Humber with 38 cases.
The UKHSA identified an increase in Salmonella Enteritidis infections caused by a single strain through whole-genome sequencing (WGS) data.
The agency has launched an investigation to identify the source of the outbreak. Initial findings suggest that the outbreak may be linked to eggs imported from outside the UK. However, the source has not been definitively established, and investigations are continuing.
Dr Kathleen O'Reilly, Associate Professor at the London School of Hygiene & Tropical Medicine, said the investigation involves identifying additional cases and examining possible common sources of infection.
Dr Damien Tully, Associate Professor at the Medical Research Council at LSHTM's Uganda Research Unit, added that the number of confirmed cases is likely to be “just the tip of the iceberg.”
Salmonella is a bacterial infection that commonly causes diarrhea and gastrointestinal illness.
Common symptoms include:
Salmonella is generally a self-limiting infection. However, young children, older adults and people with weakened immune systems can develop more severe complications.
These may include bloodstream infections, infections at other sites, sepsis and multiorgan failure.
The UKHSA stated that Salmonella Enteritidis is the most common Salmonella serovar in England and a leading cause of salmonellosis.
Like other non-typhoidal Salmonella infections, it can spread through contaminated food, including:
The bacteria can also spread through contact with contaminated environments or from person to person.
Dr O'Reilly advised fully cooking eggs before eating them and maintaining good food hygiene.
Key precautions include:
People who develop diarrhea or stomach cramps should rest and drink plenty of fluids. Young children, older adults and other vulnerable people who become ill should seek medical advice.
The US is also experiencing a Salmonella outbreak linked to eggs. The US Food and Drug Administration (FDA) upgraded the recall to its highest risk level and classified nearly 1.6 million dozen eggs as “Class I.” The agency defines a Class I recall as a situation in which there is a reasonable probability that exposure to the affected product could cause serious adverse health consequences or death.
The FDA said illness usually occurs 12 to 72 hours after consuming food contaminated with Salmonella, with symptoms typically lasting four to seven days.
Credit: AI
For people living with alopecia areata, hair loss can be unpredictable, persistent, and difficult to treat. Now, amid lack of a definitive cure, a medicine originally developed for inflammatory diseases such as rheumatoid arthritis, is showing striking results in patients with severe alopecia areata.
Two large Phase III clinical trials involving 1,399 adults and adolescents found that the drug upadacitinib significantly improved scalp hair regrowth compared with placebo. The trial’s findings were published in JAMA Dermatology.
The results are both striking and promising as alopecia areata is an autoimmune condition, in which the immune system mistakenly attacks hair follicles.
Upadacitinib, sold under the brand name Rinvoq, belongs to a class of medicines called JAK inhibitors.
JAK proteins help transmit signals that are involved in immune and inflammatory responses. In alopecia areata, abnormal immune response contributes to the attack on hair follicles.
By blocking JAK1 signaling, upadacitinib can slow down some of these immune responses, potentially allowing damaged or suppressed hair follicles to resume producing hair for some time.
The drug is already used for other autoimmune conditions including rheumatoid arthritis, Crohn's disease and ulcerative colitis.
Its potential use in alopecia is an example of drug repurposing, where an existing medicine gets used for a completely different disease.
Also read: Going Slow & Steady Really Help With Sustainable Weight Loss? New Study Challenges The Norm
The Phase III programme included two parallel trials, UP-AA1 and UP-AA2, involving adults and adolescents with severe alopecia areata.
After 24 weeks, about 45% of patients taking 15 mg of upadacitinib achieved at least 80% scalp hair coverage. More than 54% of those taking 30 mg reached the same threshold.
In comparison, only about 2% of placebo recipients achieved that level of regrowth.
Researchers also reported improvements in eyebrow and eyelash hair and indirectly in quality of life
Strikingly, benefits were seen in people with severe disease, rather than only those with a few small bald patches. Severe alopecia areata in the trials was defined as hair loss affecting at least half of the scalp.
Also read: Meniscus Tears: Why Runners & Athletes Shouldn't Ignore This Common Knee Injury
Alopecia areata currently has no guaranteed permanent cure. And this trial does not mean that the condition can be cured.
The disease can follow a relapsing and unpredictable course, with hair growing back and then falling out again.
The new findings show that upadacitinib can promote substantial hair regrowth while patients are receiving treatment. They do not prove that the underlying autoimmune disease can be permanently eliminated.
There are already approved JAK inhibitors for alopecia areata, including baricitinib, ritlecitinib and deuruxolitinib, so upadacitinib would not be the first drug in this category.
The safety findings in the trials were consistent with the known safety profile of upadacitinib, and researchers reported no new safety concerns during the study period.
Common adverse events included upper respiratory infections, acne, increased creatine phosphokinase and nasopharyngitis.
But JAK inhibitors are powerful medicines that regulates immune system and are not something people should take simply because they are experiencing hair loss. Their risks and benefits need to be assessed by a doctor.
© 2024 Bennett, Coleman & Company Limited